Gene Therapy Market Research Report Information By Product Type (Kymriah, Luxturna, Yescarta, Zolgensma, Zynteglo), By Indication (Oncology And Genetic Diseases), By End Users(Hospitals & Clinics, Specialty Treatment Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

Global Gene Therapy Market Overview

The Gene Therapy Market Size was valued at USD 0.95 billion in 2022 and is projected to grow from USD 1.13 billion in 2023 to USD 2.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6% during the forecast period (2023 - 2032). Rising number of gene therapy products approved and the rising amount of money spent on research & development are the key market drivers enhancing the market growth.Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Gene Therapy Market Trends

• Products in the pipeline is rising to boost market growth

These significant concern are attempted to be addressed by the medical fraternity. The focus of gene therapies is to treat diseases by making changes to genetic material, such as deactivating broken genes or swapping out a disease-causing gene for a healthy copy. A variety of illnesses are being treated with gene therapy, which has proven to be beneficial. Diabetes, cancer, heart disease, and AIDS can all be cured with this of therapy.

Additionally, the gene therapy market will Bennett from improved regulatory backing during the projection period. The methods used by some of regulatory agencies to advertise treatments have improved. One of the instances is the FDA’s support for CAR-T technology. Regulators permit flexibility in the conventional hierarchy of how clinical trials particularly in phase II and III research. In addition, the FDA anticipated that by 2025, 10 to 20 novel cell and gene therapies would be approved annually. DNA sequencing has brought about a paradigm shift in proteomics and genomics research

Additionally, increased funding and investments in this industry will offer market participants significant growth potential. For the launch of innovative products, several biopharma businesses are investing in the area. For instance, Ori Biotech raised more than USD 100.0 million in Series B funding in January 2022 to launch a cutting-edge platform for researching cell and gene therapies. With the help of this cash, pre-commercialization, and market launch might happen quickly. Therefore, a medical condition related to gene therapy has recently enhanced the gene therapy market CAGR globally.

However, there have been significant advances in treatment innovations to cater to the demand. For instance, there have been several introductions of biomaterial gene therapy implants, another factor driving the growth of the Gene Therapy market revenue.

Gene Therapy Market Segment Insights

Gene Therapy Product Type Insights

The gene therapy market segmentation, based on product type, includes kymriah, luxturna, yescarta, zolgensma, strimvelis, zynteglo and others. Tisagenlecleucel, marketed as Kymriah, is a treatment for B-cell acute lymphoblastic leukemia (ALL) which uses the body’s own T cells to fight cancer (adoptive cell transfer). Luxturna (voretigene neparvovec-rzyl) is currently the only approved gene therapy available in the US. It is the first medication approved for an inherited genetic disease ever.

May 2022:KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of therapy

June 2022:For the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.

Gene Therapy Indication Type Insights

The gene therapy market segmentation, based on type, oncology diseases, and others. Spinal muscular atrophy (SMA) is the segment leader in 2022, with a share of 43.44%. SMA is one of the infancy’s most frequent fatal hereditary disorders, even though it is rare. The creation of Zolgensma (AVXS-101) has demonstrated its capability to cure SMA and modify the phenotype of the disease effectively. In May 2019, the FDA approved Zolgensma, a drug developed by Novartis that targets the root cause of SMA.

The only gene therapy in this area to date receive approval is Zolgensma. Accepting this gene therapy proves that treatments for severe genetic diseases like SMA are becoming more common. Hence, the rising Indication of material for Gene Therapy positively impacts market growth.

March 2020:Gene Therapy company is testing its antibiotic in phase 1 trials for the treatment of multi-drug resistant infections in collaboration with the nonprofit initiatives CARB-X and the Antibiotic Research and Development Partnership (GARDP).

Figure 1: Gene Therapy Market, by Indication 2022 & 2032 (USD billion)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Additionally, the inherited retinal disease is also anticipated to experience a high CAGR during the projection period. The market has been driven by increased R&D efforts to create gene therapies that treat ocular illnesses, mainly hereditary retinal diseases. Spark therapeutics is marketing Luxturna in the United States as a therapy for a retinal genetic illness, while Novartis is marketing it outside. With its approval, Luxturna could target a genetic condition brought on by mutations in a single genetic component for the rst time with natural gene therapy.

Cervical Fusion End User Insights

Based on end users, the gene therapy industry clinics & hospitals , market share for adeno-associated virus (AAV) vectors is anticipated to grow significantly. AS these viruses have the best effectiveness in delivering the gene to the Region of interest, AAVs are in high demand, and their utilization in clinical trials is growing yearly. The growth results from clinical trials about the advancement of gene therapy treatments for orthopedic and ophthalmic conditions have revealed enhanced efficiency. Recent years have seen a marked increase in the use of AAV across many therapeutic sectors; as a result, adoption rates are expected to increase considerably over the next few years.

Gene Therapy Regional Insight

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America gene therapy Largest Region market accounted for USD 1.13 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. . The prevalence of chronic diseases is increasing, healthcare spending is rising and increasing, there is a Sophisticated healthcare infrastructure, reimbursements are available, and there are significant market players. Therefore North America market expand throughout the forecast period.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: GENE THERAPY MARKET SHARE BY REGION 2022 (%)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe gene therapy market accounts for the second-largest market share due to the availability of cutting-edge treatment facilities and government backing for the growth of the healthcare industry. Further, the Germany market of gene therapy held the largest market share, and the UK market of gene therapy was the fastest growing market in the European region

The Asia-Pacific gene therapy Market is expected to grow at the fastest CAGR from 2023 - 2032, Asia-Pacific is anticipated to have the most rapid growth rate. Due to the easy access to resources, the presence of big corporations locally, and rising government funding. Moreover, China market of gene therapy held the largest market share, and the India arket of gene therapy was the fastest growing market in the Asia-Pacific region

For instance, India market of gene therapy is the favored destination for medical travelers due to the availability of surgeons, cutting-edge technology, & cost-effective treatments. On the other hand, Singapore is famous for the presence of well-trained doctors, state-of-the-art facilities, and quality care. As per the data cited in the Medical Tourism Index 2022-21 published by the Medical Tourism Association in July 2022, Singapore is ranked in 2nd position, Japan at 3rd, India at 10th, South Korea at 14th, and China at 33rd out of the top 46 international healthcare destinations. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2023–2032.

Gene Therapy Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market growth for Gene Therapy. Market participants are also taking various strategic initiatives to expand their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Gene Therapy Industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies manufacturers adopt in the Gene Therapy industry to Benet clients and expand the market sector is manufacturing locally to reduce operating costs. In recent years, the Gene Therapy industry has provided medicine with some of the most significant. The Gene Therapy market major player such as Amgen Inc. (US), Bristol-Myers Squibb Company (US), Gilead Sciences Inc. (US), and others are working on expanding the market demand by investing in research and development activities.

Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, in uenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500. For instance, SANTA MONICA, Calif.—(BUSINESS WIRE)—Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus®(brexucabtagene autoleucel).

Also, Amgen focuses on areas of high unmet September 2022, data from a latest age study showed the company’s cancer pill Lumakras beating out chemotherapy. The was the approved drug in the set of treatments that target KRAS, among the most common genetic mutations found in cancers but one which researchers have struggled for years to design drugs to treat. The drug was approved in 2021 with a list price of $17,900 per month in September 2022.

Key Companies in the Gene Therapy market includes

• Amgen Inc. (US)


• Spark Therapeutics Inc. (US)


• Bristol-Myers Squibb Company (US)


• Novartis AG (Switzerland)


• 
  Gilead Sciences Inc. (US)


• Celgene Corporation (US)


• Thermo Fisher Scientific Inc. (US)


• CEVEC (Germany)


• 
  uniQure N.V. (Netherlands)


• Orchard Therapeutics plc (UK)

Gene Therapy Industry Development

October 2023: Spark Therapeutics announced a partnership with Splice Bio to licence their proprietary splicing platform to develop a novel gene therapy for renal disease.  

April 2023: Bristol Myers Squibb acquired Novartis' manufacturing facility in Illinois, US to further augment its manufacturing capabilities for hard to manufacture gene therapies. 

June 2023: The US FDA approved Elevidys, the first ever gene therapy for treating Duchenne Muscular Dystrophy. The product is manufactured by Sarepta Therapeutics, Inc..

May 2022:Novartis AG (Switzerland) received FDA approval for KYMRIAH for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Gene Therapy Market Segmentation

Gene Therapy Product Type Outlook

• 
  

  Kymriah

  
  


• 
  

  Luxturna

  
  


• 
  

  Yescarta

  
  


• 
  

  Zolgensma

  
  


• 
  

  Strimvelis

  
  


• 
  

  Zynteglo

  
  

Gene Therapy Indication Type Outlook

• 
  

  Oncology

  
  


• 
  

  Genetic Diseases

  
  

Gene Therapy End User Outlook

• 
  

  Hospitals & Clinics

  
  


• 
  

  Specialty Treatment Centers

  
  

Gene Therapy Regional Outlook

North America

• US


• Canada

Europe

• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe

Asia-Pacific

• China


• Japan


• India


• Australia


• South Korea


• Rest of Asia-Pacific

Rest of the World

• Middle East


• Africa


• Latin America